

Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria

NCT03301038

Status	RECRUITING
Phase	Phase 2
Sponsor	Children's Hospital of Philadelphia
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (5)

- Males or females age 6 months to 65 years.
- at least one mutations of CYP24A1
- Serum and/or urinary calcium above the normal reference range for age
- Serum PTH concentration ≤ 20 pg/ml
- Elevated or normal serum concentration of 1,25-dihydroxyvitamin D3.

Exclusion (6)

- Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
- Allergy to rifampin or related medications
- Current therapies with medications that have significant drug-drug interactions with rifampin, defined as a medication considered to interact with CYP3A4 or CYP3A5 and either induce or inhibit expression or function of these P450 enzymes. By "drug-drug" interactions we are looking for medications that will affect metabolism or action of rifampin as exclusionary, not medications that will be affected by rifampin.
- Pregnancy or breastfeeding
- Laboratory abnormalities that indicate clinically significant hepatic, or renal disease:
... and 1 more (see full listing online)

Locations (1 total)

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States